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Akkermansia muciniphila and Faecalibacterium prausnitzii, cohabitants in the intestinal
mucosa, are considered members of a healthy microbiota and reduction of both species
occurs in several intestinal disorders, including inflammatory bowel disease. Little is
known however about a possible link between the reduction in quantity of these
species, and in which circumstances this may occur. This study aims to determine the
abundances and co-occurrence of the two species in order to elucidate conditions that
may compromise their presence in the gut. Loads of A. muciniphila, total F. prausnitzii and
its two phylogroup (16S rRNA gene copies) were determined by quantitative polymerase
chain reaction in colonic biopsies from 17 healthy controls (H), 23 patients with ulcerative
colitis (UC), 31 patients with Crohn’s disease (CD), 3 with irritable bowel syndrome
(IBS) and 3 with colorectal cancer (CRC). Data were normalized to total bacterial 16S
rRNA gene copies in the same sample. Prevalence, relative abundances and correlation
analyses were performed according to type of disease and considering relevant clinical
characteristics of patients such as IBD location, age of disease onset, CD behavior,
current medication and activity status. Co-occurrence of both species was found in 29%
of H, 65% of UC and 29% of CD. Lower levels of total F. prausnitzii and phylogroups
were found in subjects with CD, compared with H subjects (P ≤ 0.044). In contrast,
no differences were found with the regard to A. muciniphila abundance across different
disease states, but CD patients with disease onset below 16 years of age featured a
marked depletion of this species. In CD patients, correlation between A. muciniphila
and total F. prausnitzii (ρ = 0.362, P = 0.045) was observed, and particularly in
those with non-stricturing, non-penetrating disease behavior and under moderate
immunosuppressants therapy. Altogether, this study revealed that co-occurrence of both
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species differs between disease status. In addition, IBD patients featured a reduction of
F. prausnitzii but similar loads of A. muciniphila when compared to H subjects, with the
exception of those with early onset CD. Depletion of A. muciniphila in this subgroup
of subjects suggests that it could be a potential biomarker to assist in pediatric CD
diagnosis.
Keywords: Akkermansia muciniphila, Faecalibacterium prausnitzii, Crohn’s disease, ulcerative colitis,
inflammatory bowel diseases
INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) are the
two major types of idiopathic inflammatory bowel diseases
(IBD) (Mendoza Hernández et al., 2007). Both are chronic
inflammatory disorders of the gut. UC typically begins in the
rectum and inflammation may extend continuously to involve
the entire colon. In 20% of CD patients the disease affects the
colon exclusively (Silverberg et al., 2005), but themost commonly
involved areas are terminal ileum and the beginning of the colon.
In CD any part of the gastrointestinal tract (from the oropharynx
to the anus) may be affected in a patchy pattern (Mendoza
Hernández et al., 2007). Other than location, differences in the
mucosal lesions exist between these conditions. Inflammation in
CD can be transmural reaching the serosa, whereas inflammation
in UC patients is generally restricted to the mucosa.
The inner layer of the bowel wall is a niche of particular
importance, because of the spatial proximity between epithelial
cells and gut bacteria, and thus the study of human intestinal
mucosa biopsies provides meaningful insights of host-bacterial
interactions. Numerous studies have been prompted over the last
decade aiming at deciphering the exact role of gut microbiota
in IBD. Nowadays there is a wide variety of clinical and
experimental studies revealing microbial implication in IBD
(Sartor, 2006, 2008; Seksik et al., 2006; Manichanh et al., 2012).
The most replicated finding by far has been disturbances in the
intestinal microbiota composition balance, situation known as
dysbiosis (Gophna et al., 2006; Manichanh et al., 2006; Martinez-
Medina et al., 2006; Andoh et al., 2009; Willing et al., 2009;
Sokol and Seksik, 2010; Joossens et al., 2011; Mondot et al., 2011;
Machiels et al., 2013). In this state, dominating species, to whom
a beneficial role to preserve gut homeostasis has been attributed,
become underrepresented.
Akkermansia muciniphila inhabits mainly in the mucosa, and
represents between 1 and 3% of the gut microbiota (Derrien et al.,
2004, 2008). A decrease of this species has been demonstrated
in feces and/or biopsies of several disorders including autism,
obesity, type 2 diabetes, appendicitis, and IBD (Belzer and de Vos,
2012; Everard et al., 2013). Studies in mice models have shown
that gut colonization by this species affects expression of genes
involved in immune response-regulatory processes (Derrien
et al., 2011) as well as in host’s lipid metabolism (Lukovac et al.,
2014), especially in the colon. It is of note that extracellular
vesicles derived from this species have a protective function
that ameliorates severity of induced colitis in mice, suggesting
that it has an important role in the maintenance of intestinal
homeostasis (Kang et al., 2013). A. muciniphila is essential for
a healthy mucus layer in the human gut in terms of mucus
production and thickness (Belzer and de Vos, 2012). This species
is not only important for the host, but also for gut microbial
community. Its specific capability to degrade mucus results in the
release of oligosaccharides and the production of propionate and
acetate (Derrien et al., 2004) as well as amino acids, important co-
factors and vitamins (van Passel et al., 2011) that become available
for other gut symbionts. However, significant co-occurrence of
this species with other bacterial taxa present in the gut has not
been revealed in feces (Lozupone et al., 2012).
In turn, Faecalibacterium prausnitzii is also an abundant
intestinal microorganism with a feco-mucosal distribution, and
whose relative abundance can represent between 2 and 15%
of intestinal bacterial communities (Swidsinski et al., 2005;
Baumgart et al., 2007; Flint et al., 2012). Several studies, of
fecal and/or mucosal samples, have shown that F. prausnitzii
prevalence and abundance are reduced under certain disorders
such as celiac disease (Swidsinski et al., 2008; De Palma et al.,
2009), obesity and type 2 diabetes (Furet et al., 2010; Graessler
et al., 2012), appendicitis (Swidsinski et al., 2011), chronic
diarrhea (Dörffel et al., 2012), irritable bowel syndrome (IBS) of
alternating type (Rajilic´-Stojanovic´ et al., 2011), colorectal cancer
(CRC) (Balamurugan et al., 2008; Lopez-Siles et al., 2016), and
particularly in IBD (Sokol et al., 2008, 2009; Swidsinski et al.,
2008; Willing et al., 2009; Machiels et al., 2013; Lopez-Siles et al.,
2014). Low abundance of this species has been linked with active
IBD (Sokol et al., 2009), and some complications such as a higher
risk of post-operative recurrence (Sokol et al., 2008) or pouchitis
(McLaughlin et al., 2010). Other than butyrate production (which
can reduce intestinal mucosa inflammation and is the main
energy source for the colonocytes), additional anti-inflammatory
properties have been attributed to F. prausnitzii (Sokol et al.,
2008; Miquel et al., 2013; Martín et al., 2014). Both, cell and
supernatant fractions of this species, have been proven to
reduce severity of acute (Sokol et al., 2008; Rossi et al., 2015),
chronic (Martín et al., 2014) and low grade (Martín et al.,
2015) inflammation in murine models. This has been attributed
to an enhancement of intestinal barrier function related with
the expression of certain tight junction proteins other than
claudin (Carlsson et al., 2013). F. prausnitzii also influences gut
physiology through the production of mucus O-glycans, and
may help to maintain suitable proportions of different cell types
of secretory linage in the intestinal epithelium, as evidenced in
rodent studies (Wrzosek et al., 2013). To date, it remains unclear
which conditions are likely to compromise this species in the
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gut. Alterations in gut pH or bile salt concentration have been
suggested (Lopez-Siles et al., 2012), but a break in the ecologic
relations with other gut symbionts that support its presence
in the gut may also contribute, but have been little studied.
Co-occurrence network analysis of gut bacteria found in feces,
showed that F. prausnitzii co-occurs with several members of the
C. coccoides group and Bacteroidetes (Lozupone et al., 2012). As
F. prausnitzii growth is stimulated by acetate (Duncan et al.,
2002), its presence in the gut may also be favored by acetate
producers like A. muciniphila. However, little is known about
interaction between these two species.
This work is aimed at determining the variation of mucosa-
associated A. muciniphila and F. prausnitzii between healthy
control subjects (H) and patients suffering from IBD, in order
to elucidate in which conditions imbalances of these species
take place, and if both species are affected equally. Some IBS
and CRC patients have been included for comparative purposes.
Prevalence and abundance of mucosa-associated A. muciniphila
and F. prausnitzii have been determined in colonic samples
by quantitative polymerase chain reaction (qPCR). Data have
been analyzed taking into account patients’ most relevant clinical
characteristics. Medication at sampling was also considered in
order to determine if any of the current therapies are effective
in restoring these species levels to those found in H. In addition,
correlation analysis of their load has also been conducted to
provide supporting evidence on the effect of one population over
the other, or about whether or not they are influenced by similar
gut factors.
MATERIALS AND METHODS
Patient Recruitment and Characteristics
The study population was a cohort consisting of Spanish
volunteers including 54 IBD (31CD and 23 UC), three IBS, three
CRC patients and 17H (Table 1). Subjects were gender matched
for all the groups. Concerning age, CD patients were younger
than those in the H group (P = 0.002), whereas CRC patients
were significantly older than those with IBD (P≤ 0.028). Besides,
at disease onset, CD patients were younger than UC (mean age±
SD; UC= 37.2± 13.3 years, CD= 28.0± 12.4 years; P= 0.012).
Subjects were recruited by the Gastroenterology Services
of the Hospital Universitari Dr. Josep Trueta (Girona, Spain)
and the Hospital Santa Caterina (Salt, Spain) between 2006
and 2010. To avoid bias between centers, patients with IBD
were diagnosed according to standard clinical, pathological,
and endoscopic criteria and categorized according to the
Montreal classification (Silverberg et al., 2005). IBS patients
were diagnosed according to Rome III criteria (available at
http://www.romecriteria.org/criteria/). The diagnosis of CRC
was established by colonoscopy and biopsy, and data correlated
with high risk of developing this disease was recorded. Controls
consisted of subjects who underwent colonoscopy for different
reasons as rectorrhagia (n = 8), colorectal cancer familial
history (n = 3), and abdominal pain (n = 6), and all featured
normal colonoscopy. Clinically relevant data of all the patients
was collected (Table 1). Percentage of active patients was
higher in CD patients than in UC (P = 0.036). Individuals
included in this study were >18 years old, did not have
any other intestinal disease and were not pregnant. Antibiotic
treatment within 2 months before colonoscopy was an exclusion
criterion.
Ethics Statement
This work was approved by the Ethics Committee of Clinical
Research of the Hospital Universitari Dr. Josep Trueta (Girona,
Spain) and the Institut d’Assistència Sanitària of Girona (Salt,
Spain) on 26th May 2006 (protocol code BACTECCU, Ref CEIC:
08/06) and 21st April 2009 (protocol code BACTODIAG, Ref
CEIC: 10/08), respectively. All subjects gave written informed
consent in accordance with the Declaration of Helsinki.
Sample Collection and DNA Extraction
Cleansing of the gastrointestinal tract using Casenglicol R©
was performed prior to colonoscopy, following manufacturer’s
guidelines. During routine endoscopy and following standard
procedures, a biopsy (<25mg) from non-affected tissue of the
colon was taken for each subject. All biopsies were immediately
placed in sterile tubes without any buffer. Following completion
of the whole endoscopic procedure, all samples were stored at
−80◦C upon analysis.
To discard transient and loosely attached bacteria, biopsies
were subjected to two mild ultrasound wash cycles, as reported
previously (Martinez-Medina et al., 2006). Afterwards, DNA
was extracted using the NucleoSpin R© Tissue Kit (Macherey-
Nagel GmbH & Co., Duren, Germany). The support protocol
for Gram positive bacteria (consisting of pre-incubation during
1 h at 37◦C with buffer T1 (20mm Tris/HCl, 2mM EDTA,
1% Triton X-100, pH 8) supplemented with 20 mg/ml
lysozyme), and the RNAse treatment step were carried out.
Genomic DNA was eluted with 10mM Tris-HCl (pH 7.4) and
stored at −80◦C until use. DNA concentration and purity
of the extracts were determined with a NanoDrop ND-100
spectrophotometer (NanoDrop Technologies, USA). The average
purity and concentration of the DNA extracts was (mean ± SD)
1.794 ± 0.579 Abs260/280 ratio and 174.864 ± 131.829 ng/µl,
respectively.
Quantification Standards for qPCR
Standard DNA templates from F. prausnitzii strain S3L/3
(phylogroup I), F. prausnitzii DSM 17677 (phylogroup II)
and A. muciniphila (ATCCBAA-835) were prepared as genetic
constructs after PCR amplification of the whole 16S rRNA
as previously reported (Lane, 1991; Weisburg et al., 1991),
and subsequent insertion of this gene into a pCR R©4-TOPO R©
cloning plasmid (Invitrogen, CA, USA) following manufacturer’s
guidelines.
After purification with the NucleoSpin R© Plasmid kit
(Macherey-Nagel GmbH & Co., Duren, Germany), plasmids
were linearized with SpeI and quantified using QubitTM
Quantitation Platform (Invitrogen, Carlsbad, USA). Initial
target concentration was inferred taking into consideration the
theoretical molecular weight (3.58 × 106 Da) and the size of
recombinant plasmid (5421 pb).
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TABLE 1 | Sample size and clinical characteristics of subjects.
Healthy Irritable bowel syndrome Colorectal cancer IBD P-value§
Ulcerative colitis Crohn’s disease
n (patients) 17 3 3 23 31
Age (mean years ± SD) 48.1 ± 15.8 35.0 ± 7.0 69.3 ± 16.0 40.5 ± 13.5 33.6 ± 12.2 0.002**
Male (n, %) 10 (58.8%) 1 (33.3%) 3 (100%) 13 (56.5%) 20 (64.5%) 0.826†
Active (n, %) na na na 3 (13.0%) 13 (41.9%) 0.036†
Previous surgery (n, %) na na na 1 (4.3%) 6 (19.4%) 0.213†
Smokers (n, %) 0 (0%) 0 (0%) 0 (0%) 2 (8.7%) 5 (16.1%) 0.410†
Treatment (n, %)* 0.494†
No treatment na na na 11 (47.8%) 10 (32.3%)
Mesalazine na na na 3 (13.0%) 3 (9.7%)
Moderate immunosuppressant na na na 4 (17.4%) 10 (32.3%)
Anti-TNFα (infliximab, adalimumab) na na na 3 (13.0%) 6 (19.4%)
CD Montreal classification
Age of diagnosis (n, %)* 0.007
<16 yeays (A1) na na na na 5 (16.1%)
17–40 years (A2) na na na 11 (47.8%) 21 (67.7%)
>41 years (A3) na na na 9 (39.1%) 3 (9.7%)
Location (N, %) na
Ileal-CD (L1) na na na na 13 (41.9%)
Colonic-CD (L2) na na na na 7 (22.6%)
Ileocolonic-CD (L3) na na na na 10 (32.3%)
Behavior (N, %)* na
Non-stricturing, non-penetrating (B1) na na na na 19 (61.3%)
Stricturing (B2) na na na na 8 (25.8%)
UC classification (n, %)* na
Ulcerative proctitis (E1) na na na 5 (21.7%) na
Distal UC (E2) na na na 11 (47.8%) na
Extensive UC or ulcerative pancolitis (E3) na na na 6 (26.1%) na
IBD, Inflammatory bowel disease; TNF, tumor necrosis factor; na, not applicable.
*Medical treatment at the time of sampling was available in 21/23 UC, and 29/31CD patients; Age of disease onset was available for 20/23 UC patients, and 29/31CD patients; Disease
behavior at last follow-up before the time of sampling was available in 27/31CD patients, and none had penetrating CD (B3); Maximal disease extent at the time of sampling was
available in 22/23 UC and 30/31CD patients.
§Groups were compared by appropriate statistical tests, and P-value ≤ 0.05 was considered significant, †χ2 test, **ANOVA. Analyses statistically significant are highlighted in boldface.
Standard curves were obtained from 10-fold serial dilutions
of the titrated suspension of linearized plasmids. Strains
used to construct each standard curve are indicated in
Table 2. To prepare the standard curve, only dilutions
within the linear dynamic range span of each reaction
were used, as detailed in Table 2. Total bacteria 16S
rRNA gene quantification was used to intercalibrate all
the standard curves, in order to make sure that results
obtained were comparable. Accordingly, plasmid preparations
for A. muciniphila standard and phylogroups standards
were run as unknown samples in a total bacterial qPCR.
Specific intercalibration of total F. prausnitzii qPCR was
not required as it uses the same standard curve template
employed for total bacterial qPCR (Table 2). Quantification
values obtained were compared to initial target concentration
inferred from DNA concentration, and <10% variation was
obtained.
qPCR Assays
Previously reported 16S rRNA gene-targeted primers and probes
were used for total F. prausnitzii (Lopez-Siles et al., 2014),
phylogroups (Lopez-Siles et al., 2016), A. muciniphila (Collado
et al., 2007) and total bacterial (Furet et al., 2009) quantification
through qPCR.
Amplification reactions were performed as described
elsewhere (Collado et al., 2007; Furet et al., 2009; Lopez-Siles
et al., 2014, 2016) with slight modifications detailed in Table 2.
Briefly, quantifications were carried out in a total volume of 20µl
reactions containing: 1× TaqMan R© Universal PCR Master Mix
2× or SYBR R©Green PCR Master Mix 2× (Applied Biosystems,
Foster City, CA, USA) as required, 300–900 nM of each primer
and 250–300 nM of probe if necessary. Up to 50 ng of genomic
DNA template was added in each reaction. All primers and
probes used in this study as well as PCR conditions are detailed
in Table 2. Total F. prausnitzii, and total bacteria primers and
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hydrolysis probes were purchased from Applied Biosystems
(Foster City, CA, USA), whereas primers and hydrolysis
probes for F. prausnitzii phylogroups and A. muciniphila
were acquired from Biomers (Ulm, Germany). DNA of the
internal amplification control (IAC) was synthesized by Bonsai
technologies group (Alcobendas, Spain). All oligonucleotides
were purified by HPLC. Plates and optical caps were provided
by Applied Biosystems (Ref. 4323032 and Ref. 4306737,
respectively).
Samples were run at least in duplicate in the same plate
(Table S1), which was set up manually. For data analysis, the
mean of the quantifications was used. Duplicates were considered
valid if the standard deviation between quantification cycles
(Cq) was <0.34 (i.e., a difference of <10% of the quantity was
tolerated), and if not quantification was repeated. Quantification
controls consisting of at least five reactions with a known
number of target genes were performed to assess inter-run
reproducibility. Inhibition was controlled on total F. prausnitzii
quantification by adding 103 copies of an internal amplification
control (IAC) template to each reaction. It was considered that
there was no inhibition if the obtained Cq was <0.34 different
from those obtained when quantifying the IAC alone for any of
the replicates. In each run, a non-amplification control (NTC)
which did not contain any DNA template (either bacterial or
IAC) was also included. In all cases with hydrolysis probes, NTC
resulted in undetectable Cq values whereas for SYBRGreen assays
NTC had Cq >35, and melting curve analysis confirmed no
specific amplification.
A 7500 Real Time PCR system (Applied Biosystems, USA)
was used to perform all qPCR. The thermal profile used for
each assay is detailed in Table 2. In summary, it consisted
of a first step at 50◦C during 2min for amperase treatment
followed by a 95◦C hold for 10min to denature DNA and
activate Ampli-Taq Gold polymerase; and a further 40–50 cycles
consisting of a denaturation step at 95◦C for 15 s, followed by an
annealing and extension step at 60◦C (or at 64◦C for phylogroups
quantification) for 1min. When required, melting curve analysis
was performed to assess whether or not fluorescence was
due to specific amplification products. Data were collected
and analyzed using the 7500 SDS system software version 1.4
(Applied Biosystems). Assays were performed under average
PCR efficiencies of (mean± SD) 89.9± 4.6% (Figure S2).
Data Normalization and Statistical Analysis
Regarding the qualitative analyses, absence of F. prausnitzii, its
phylogroups orA.muciniphilawas considered if no detection was
obtained during the qPCR analysis, corresponding to samples
that carried these bacteria below the detection limit (i.e., 106.6,
1.10, 2.39, and 374.09 16S rRNA genes per reaction for total
F. prausnitzii, phylogroup I, phylogroup II, and A. muciniphila,
respectively). Pearson’s χ2 test was used to compare the
prevalence between groups of patients, by IBD disease location,
age of disease onset and other clinically relevant data as activity,
treatment and whether or not patients have had intestinal
resection.
Referring to quantitative analyses, total F. prausnitzii,
phylogroups and A. muciniphila 16S rRNA gene copy detected
in each sample were normalized to the total bacterial 16S
rRNA gene copies in the same sample. Data are given as the
log10 of the ratio between 16S rRNA gene copies of the target
microorganism and million of total bacterial 16S rRNA genes
detected in the same sample. No further correction to adjust
for differences in 16S rRNA gene operons in each species was
performed, as no consensus has been achieved to date for
F. prausnitzii according to rrnDB (Stoddard et al., 2015). For
those samples with no detection of F. prausnitzii, phylogroup
or A. muciniphila, the number of copies corresponding to their
respective detection limit was used for calculations of relative
abundances. Kruskal–Wallis non-parametric test was applied to
assess differences in variables with more than two categories such
as diagnostics, CD and UC disease location, age of disease onset,
and current medication. Mann–Whitney U test was used to
perform pairwise comparisons of subcategories of these variables,
and FDR after multiple comparisons was assessed (Table S2).
Mann–Whitney U test was also used to compare, variables with
two categories such as activity (active CD and UC patients
when CDAI > 150 (Best et al., 1976) and a Mayo score >3
(Pineton de Chambrun et al., 2010), respectively), and intestinal
resection. In addition, ratios between 16S rRNA gene copies of
either total F. prausnitzii, phylogroup I or phylogroup II and
A. muciniphila were calculated and analyzed as detailed above.
Spearman correlation coefficient and significance between total
F. prausnitzii, or phylogroup quantities and A. muciniphila load
was calculated. The same statistical method was used to analyze
the correlation between the quantity of each bacterial group, and
continuous clinical data such as time (in years) since disease
onset. All the statistical analyses were performed using the SPSS
15.0 statistical package (LEAD Technologies, Inc.). Significance
levels were established for P ≤ 0.05.
RESULTS
Prevalence of Mucosa-Associated
A. muciniphila and F. prausnitzii
To assess co-occurrence of both species, prevalence of
F. prausnitzii (total or separating by phylogroups), and
A. muciniphila as calculated from positive determinations over
total samples, was analyzed by condition, by IBD location and
also taking into account relevant clinical data (Figure 1). Four
categories of patients were established based on: detecting only F.
prausnitzii, detecting only A. muciniphila, detecting both species,
or none of them. Most of the subjects carried both species or
F. prausnitzii alone, whilst finding A. muciniphila alone was rare
and in some cases, none of the two species was found suggesting
that if present, they are below the detection limit of our assays.
When analysing the cohort by diagnostics (Figure 1A), only
statistically significant differences in the proportions of each
category were observed for the co-occurrence of F. prausnitzii
phylogroup I and A. muciniphila (P < 0.001). As a particularity
of CD, none of the two species was detected in 51.61% of subjects
of this group, which was a higher proportion than in the other
groups of subjects (ranging from 4.35% to 33.3%). In 64.71% of
H subjects only one species (F. prausnitzii phylopgroup I) was
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FIGURE 1 | Prevalence of total F. prausnitzii, phylogroups and A. muciniphila in (A) each group of patients, (B) in Inflammatory bowel disease (IBD) subjects according
to whether or not ileum is affected, and (C) in IBD by age of disease onset. H, control subjects; IBS, irritable bowel syndrome; UC, ulcerative colitis; CD, Crohn’s
disease; CRC, colorectal cancer.
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detected, while this category was present in between 16% and
34% in the other groups of subjects. F. prausnitzii phylogroup
I and A. muciniphila were found in approximately 30% of H,
33.33% of IBS and 20% of CD subjects, whereas 47.82% of UC
and 66.67% of CRC patients fall into this category. Similar trends
were observed for F. prausnitzii phylogroup II andA.muciniphila
co-occurence analysis (P = 0.105), whereas percentages of each
category were more similar between groups of subjects when
analyzed in conjunction prevalence of total F. prausnitzii and
A. muciniphila (P= 0.387). Of note, all subjects with IBS or CRC
had at least one of the two species.
When analysing the cohort by IBD disease location, no
significant differences within UC and within CD subtypes
were achieved (Figure S1). However, a trend toward different
proportions was observed. Half of subjects with distal UC (E2)
were characterized by presenting onlyA.muciniphila. All patients
with UC and also those with C-CD carried at least one species,
whereas lower prevalences were found in CD patients with ileal
involvement. Particularly, none of the two species were detected
in 10–31% of CD patients with ileal disease location, whereas in
23.1% of I-CD and 40% of IC-CD, both species co-occurred. As
the frequencies observed in C-CD patients resembled in some
cases those in UC, we analyzed IBD subjects by grouping those
with (either I-CD or IC-CD) or without (i.e., C-CD or UC)
ileum involved (Figure 1B). Interestingly, when analyzing co-
occurrence of F. prausnitzii phylogroup I and A. muciniphila the
percentage of subjects with none or only one species detected was
over 80% in those with ileal disease whereas in approximately
40% of subjects with colonic disease both species were found
(P = 0.028).
When analyzing prevalence taking into account clinical data
of the patients, no significant differences were observed by
activity, medication or intestinal resection neither in CD nor in
UC. No differences were found within CD patients according to
disease behavior. Interestingly, A. muciniphila was not detected
in any of the CD patients diagnosed with disease onset below 16
years of age (Figure 1C). It remains to be stablished if this is a
common issue with UC patients, as none with early disease onset
was included in our cohort.
Abundances of Mucosa-Associated
A. muciniphila and F. prausnitzii
A. muciniphila, total F. prausnitzii and its phylogroups load was
compared amongst patients with different intestinal conditions
(Table 3). Total F. prausnitzii was less abundant in CRC and
IBD patients as compared to H subjects. However, statistically
significant differences were achieved only for CRC (P = 0.028)
and CD patients [P = 0.021, but not sustained after FDR
assessment (Table S2)], probably because the reduction is lower
for UC patients and the high variability between subjects. In CD
patients, those with ileal involvement presented the lowest levels
of this bacterium (P= 0.050), whereas IC-CD patients and C-CD
were similar to UC (Table 3). Slight differences in average load
were also found within UC patients although these differences
were not statistically supported. Patients with ulcerative proctitis
(E1) and extensive UC (E3) presented F. prausnitzii loads similar
to H subjects, whereas those with E2 had abundances between
CD patients and H subjects.
F. prausnitzii phylogroup I load was reduced in all groups
of patients in comparison to H subjects. This reduction was
particularly noticeable in CD and CRC patients (P < 0.008),
while in UC and IBS patients, it was observed as well, but less
apparent.When analyzing data by disease location, I-CD patients
showed the most marked reduction of phylogroup I counts in
comparison to other CD locations (P = 0.025). Values did not
differ significantly in UC patients when analyzed by location.
However, loads in E2 and E3 subjects resembled that of CD
patients, while for E1 subjects, their profiles were closer to that
observed in H subjects.
With respect to F. prausnitzii phylogroup II, its abundance
was significantly reduced in CD patients when compared to UC
subjects (P = 0.015) while similar loads were observed between
all the other groups of subjects (Table 3). Although no differences
by IBD location were found, loads tend to be lower in those with
ileal involvement (either I-CD or IC-CD, P = 0.069).
Interestingly, A. muciniphila load was similar between all the
groups of subjects and also no differences were observed between
IBD locations (P> 0.540; Table 3). In all groups of subjects, total
F. prausnitzii counts outnumbered A. muciniphila, but there was
a high variability between subjects, even within each condition.
No difference in the ratio of total F. prausnitzii: A. muciniphila
was found by group of subjects, neither when analyzing by
IBD subtypes according to disease location. In contrast, when
calculating these ratios by F. prausnitzii phylogroups, significant
differences were found between conditions (Figure 2). CD
patients, featured lower phylogroup I:A. muciniphila ratios than
H (P = 0.031), and also lower phylogroup II: A. muciniphila
ratios compared to UC (P = 0.017). When analyzing IBD groups
by disease location, no significant differences were observed,
probably due to the high dispersion of data and to the fact that
when separating by location the number of patients included
within each category is reduced. Nonetheless, subjects with a
larger disease extension, or with ileum involvement, tended to
feature lower values of both ratios. These differences in ratios
are due to differences in F. prausnitzii (or phylogroup) load, as
A. muciniphila load was similar across all subjects.
A. muciniphila and F. prausnitzii
Abundances in Relation to Patients Clinical
and Treatment Data
No differences in A. muciniphila, counts were observed in either
UC or CD patients according to activity status. Nevertheless,
those patients with active UC featured the lowest load.
F. prausnitzii and the abundance of the phylogroups did not differ
between active and inactive UC patients (Table 4). CD patients
with active disease feature lower levels of total F. prausnitzii
and phylogroups in comparison to patients in remission, but
differences did not achieve statistical significance either.
Resection in CD patients was not a determining factor for
A. muciniphila loads, either (Table 5). Instead, F. prausnitzii
abundance was lower in those CD patients that underwent
intestinal resection, with significant statistical differences for
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TABLE 3 | Abundances of mucosa-associated F. prausnitzii, its phylogroups and A. muciniphila in controls (H), irritable bowel syndrome (IBS), colorectal cancer (CRC),
Ulcerative Colitis (UC), and Crohn’s disease (CD) patients.
n patients F. prausnitzii*§ Phylogroup I*§ Phylogroup II*§ A. muciniphila
H 17 5.07 ± 0.70a 3.00 ± 0.81a 2.32 ± 1.69ab 3.49 ± 0.81
IBS 3 5.50 ± 0.16ab 2.16 ± 1.54ab 2.00 ± 1.33ab 3.63 ± 0.95
CRC 3 4.24 ± 0.34b 1.12 ± 0.91bc 2.06 ± 1.62ab 2.84 ± 1.35
UC 23 4.82 ± 0.67ab 2.16 ± 1.26ac 2.79 ± 1.07a 3.07 ± 1.14
UC location
Ulcerative proctitis (E1) 5 5.01 ± 0.20 3.07 ± 0.32 3.44 ± 0.51 2.77 ± 1.36
Distal UC (E2) 11 4.77 ± 0.61 2.41 ± 1.11 2.74 ± 0.99 3.13 ± 1.24
Extensive UC or ulcerative pancolitis (E3) 6 5.03 ± 0.76 1.18 ± 1.36 2.69 ± 1.23 3.11 ± 0.98
CD 31 4.22 ± 1.31b 1.13 ± 1.64b 1.47 ± 1.37b 3.19 ± 1.35
CD location
Ileal-CD (L1) 13 3.52 ± 1.33• 0.17 ± 1.10• 1.18 ± 1.55 2.87 ± 1.28
Colonic-CD (L2) 7 5.00 ± 0.93 1.73 ± 1.94 2.12 ± 1.36 3.33 ± 1.23
Ileocolonic-CD (L3) 10 4.47 ± 1.18• 1.87 ± 1.60 1.28 ± 1.09 3.42 ± 1.61
p-value group of subjects 0.024 0.002 0.015 0.540
p-value UC location 0.568 0.110 0.432 0.961
p-value CD location 0.050 0.025 0.349 0.538
§Mean log10 (16S rRNA gene copies/million bacterial 16S rRNA gene copies) ± standard deviations.
*Statistics was calculated separately for each variable (column). Only for those analyses statistically significant (P-value in bold), pairwise comparisons were conducted, and groups of
patients with similar abundances are indicated with the same superscript (a, b). Disease locations of UC and CD patients have been analyzed as independent groups. Similarly, patients’
subtypes with similar abundances are indicated with the same superscript (•). In both cases, groups not sharing superscript are those with statistically different median abundance
values (P-value < 0.05).
FIGURE 2 | Box and whiskers plot of the ratio total F. prausnitzii: A. muciniphila, F. prausnitzii phylogroup I: A. muciniphila, and F. prausnitzii phylogroup II:
A. muciniphila: (from left to right) by group of subjects (up) and by Inflammatory Bowel Disease subtype (down). Data are represented as log10 of each ratio. The
median is represented by the horizontal line in each box. Boxes cover the 25 and 75% quantiles, and bars show the 10 and 90% quantiles. Individual data are also
shown. Homogeneous subgroups in each plot are indicated with the same superscript. H, control subjects; IBS, irritable bowel syndrome; UC, ulcerative colitis; CD,
Croh’s disease; CRC, colorectal cancer; E1, ulcerative proctitis; E2, ulcerative left-sided colitis; E3, ulcerative pancolitis; IC-CD, ileocolonic CD, I-CD, ileal CD; C-CD,
colonic CD. A. muciniphila, 16S rRNA gene Akkermansia muciniphila; F. prausnitzii, 16S rRNA gene total Faecalibacterium prausnitzii; Phylogroup I, 16S rRNA gene
F. prausnitzii phylogroup I; Phylogroup II, 16S rRNA gene F. prausnitzii phylogroup II.
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TABLE 4 | F. prausnitzii, its phylogroups and A. muciniphila abundance in inflammatory bowel disease patients by disease activity status.
Diagnostics§ n F. prausnitzii* P-value Phylogroup I* P-value Phylogroup II* P-value A. muciniphila* P-value
UC
Active 19 4.85 ± 0.71 0.464 2.12 ± 1.35 0.787 2.76 ± 1.11 0.523 3.04 ± 1.06 0.651
Inactive 3 4.61 ± 0.52 2.39 ± 0.97 3.18 ± 1.04 2.56 ± 1.29
CD
Active 18 4.10 ± 1.42 0.650 0.86 ± 1.45 0.373 1.36 ± 1.54 0.514 3.06 ± 1.28 0.514
Inactive 13 4.39 ± 1.19 1.52 ± 1.87 1.63 ± 1.15 3.36 ± 1.48
Active CD and UC were defined when CDAI >150 (Best et al., 1976) and a Mayo score >3 (Pineton de Chambrun et al., 2010), respectively.
*Median (log10 16S rRNA gene copies/million bacterial 16S rRNA gene copies) ± standard deviations.
§UC, ulcerative colitis; CD, Crohn’s disease.
TABLE 5 | F. prausnitzii, its phylogroups and A. muciniphila abundance in inflammatory bowel disease patients depending on whether or not they have had intestinal
resection during the course of the disease.
Diagnostics§ n F. prausnitzii* P-value Phylogroup I* P-value Phylogroup II* P-value A. muciniphila* P-value
UC
Non-resected 19 4.73 ± 0.68 na 1.97 ± 1.21 na 2.79 ± 1.01 0.544 3.05 ± 1.14 na
Resected 1 4.91 3.45 2.68 4.11
CD
Non-resected 21 4.46 ± 1.33 0.239 1.33 ± 1.84 0.842 1.85 ± 1.40 0.018 3.29 ± 1.44 0.476
Resected 6 3.89 ± 1.04 1.07 ± 1.33 0.59 ± 0.44 3.46 ± 0.45
*Median (log10 16S rRNA gene copies/million bacterial 16S rRNA gene copies) ± standard deviations; na, not applicable. Analyses statistically significant are highlighted in boldface.
§UC, ulcerative colitis; CD, Crohn’s disease.
phylogroup II. Precisely, resected subjects had 10 times less
phylogroup II than those without intestinal surgery (P = 0.018)
whereas the phylogroup I load was only slightly lower in resected
than non-resected patients.
The A. muciniphila load was lower in CD patients who
presented with the disease below 16 years of age (Table 6).
This group of patients also featured very low quantities of
F. prausnitzii phylogroup I although statistical significance was
not achieved. No differences in these bacterial loads were
observed between groups of UC patients with different age
of disease onset. We also analyzed disease duration, but no
statistically significant correlation was found between any of the
bacterial loads and time of disease duration (data not shown).
Finally, data were analyzed by taking into account the
medication of the patients at the time of sampling (Table 7). No
differences in A. muciniphila, F. prausnitzii or in phylogroups
abundances were observed between medications for any IBD.
However, those UC patients that received anti-tumor necrosis
factor had the lowest levels of A. muciniphila. In contrast,
those CD patients receiving moderate immunosupressants had
lower F. prausnitzii loads than patients without treatment or
receiving therapies such as mesalazine or anti-tumor necrosis
factor.
Correlation Between A. muciniphila and
F. prausnitzii Abundances
Correlation between A. muciniphila and F. prausnitzii numbers
was analyzed to provide supporting evidence for a direct/indirect
effect of one population over the other or about a putative
common factor affecting both species populations in a given
condition (Figure 3).
No correlation between these two species was found in H or
UC patients (Figure S3). Therefore, in these conditions, factors
of the gut environment may be differentially impacting on each
species. In contrast, positive correlation of both species load was
observed in CD subjects (Figure 3). Analysis by phylogroups
indicated that A. muciniphila quantity tended to positively
correlate with phylogroup I in CD patients (P = 0.060), whereas
no significant correlation was observed with phylogroup II
(Figure S3).
Moreover, no significant correlation between the two species
was observed, when splitting subjects by activity status or
whether or not they have had intestinal resection. Of note, a
positive correlation between A. muciniphila and F. prausnitzii
(particularly phylogroup I) was observed in CD patients with
non-stricturing, non-penetrating disease (B1) and in those under
moderate immunosuppressants (ρ ≥ 0.539, P ≤ 0.017). In
contrast, in UC patients with disease onset between 17 and
40 years of age, a negative correlation between A. muciniphila
and F. prausnitzii phylogroup II was observed (ρ = −0.673,
P = 0.023).
DISCUSSION
A. muciniphila and F. prausnitzii are two symbiotic and
numerically abundant members of the gut microbiota, and both
have been associated with dysbiosis in several disease conditions,
including IBD. Their niche is close to the intestinal mucosa,
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TABLE 6 | F. prausnitzii, its phylogroups and A. muciniphila abundances in inflammatory bowel disease patients by age of disease onset.
Diagnostics§ n F. prausnitzii* P-value Phylogroup I* P-value Phylogroup II* P-value A. muciniphila*# P-value
UC
17–40 years (A2) 11 4.87 ± 0.47 0.676 2.52 ± 1.09 0.171 3.12 ± 0.88 0.305 2.93 ± 1.19 0.569
>41 years (A3) 9 4.64 ± 0.91 1.65 ± 1.42 2.58 ± 1.10 2.88 ± 1.07
CD
<16 years (A1) 5 3.62 ± 1.59 0.004 ± 0.44 1.65 ± 1.71 1.76 ± 0.73a
17–40 years (A2) 21 4.26 ± 1.36 0.562 1.40 ± 1.87 0.112 1.30 ± 1.34 0.547 3.31 ± 1.16b 0.030
>41 years (A3) 3 4.67 ± 0.71 0.97 ± 0.48 2.26 ± 1.47 4.20 ± 2.15b
*Median (log10 16S rRNA gene copies/million bacterial 16S rRNA gene copies) ± standard deviations.
§UC, ulcerative colitis; CD, Crohn’s disease.
#Statistics was calculated separately for each variable (column). Groups of patients with similar abundances of A. muciniphila are indicated with the same superscript (a, b) whereas
groups not sharing superscript are those with statistically different median abundance values (P < 0.05). Analyses statistically significant are highlighted in boldface.
TABLE 7 | F. prausnitzii, its phylogroups and A. muciniphila abundances in inflammatory bowel disease by medication at sampling.
Diagnostics§ n F. prausnitzii* P-value Phylogroup I* P-value Phylogroup II* P-value A. muciniphila P-value
UC
No treatment 11 4.81 ± 0.72 1.94 ± 1.35 2.74 ± 1.13 3.10 ± 1.11
Mesalazine 3 4.87 ± 0.40 0.783 2.30 ± 0.97 0.578 3.20 ± 1.01 0.639 3.53 ± 1.82 0.387
Mod. Immsup 4 4.95 ± 0.61 2.97 ± 0.33 3.18 ± 1.54 3.06 ± 0.51
Anti-TNF 3 4.35 ± 0.96 1.53 ± 1.85 2.37 ± 1.03 2.10 ± 1.52
CD
No treatment 10 4.30 ± 1.51 1.04 ± 1.96 1.67 ± 1.61 2.69 ± 1.08
Mesalazine 3 5.00 ± 0.41 0.537 1.30 ± 1.67 0.975 2.24 ± 1.89 0.719 3.90 ± 2.20 0.125
Mod. Immsup 10 3.84 ± 1.21 0.99 ± 1.50 1.15 ± 1.09 3.72 ± 0.97
Anti-TNF 6 4.31 ± 1.68 1.42 ± 1.76 1.60 ± 1.42 2.72 ± 1.78
*Median (log10 16S rRNA gene copies/million bacterial 16S rRNA gene copies) ± standard deviations.
§UC, ulcerative colitis; CD, Crohn’s disease; Mod. Immsup, moderate immunosuppresants; Anti-TNF, Anti-tumor necrosis factor.
and therefore it can be hypothesized that they may play a key
role in cross-talk with the host. Both species are considered to
have a part in a well-functioning gut and thus are considered
as promising next generation probiotics (Neef and Sanz, 2013;
Martín et al., 2017). In the present study we have analyzed the
prevalence and abundance of mucosa associated A. muciniphila,
total F. prausnitzii and phylogroup in H and IBD subjects, taking
into account the diversity of disease locations and the clinical
features of patients. Some IBS and CRC have been included as
well, but only for illustrative purposes given the low number
of patients engaged. The abundance of both species has been
previously reported to be reduced in several intestinal disorders
(Belzer and de Vos, 2012; Miquel et al., 2013), but here for
the first time we correlate the load of both species. Through
analysis of clinical data, we consider which particular conditions
this underrepresentation is favored, and whether or not the
imbalance of one species is linked to changes in the abundance
of the other.
Our data show that the A. muciniphila load in the mucosa
of H subjects is slightly higher (2.0- to 4.5-fold, respectively)
than in IBD and CRC patients, but is not statistically significant.
An increase in A. muciniphila abundance in CRC patients
compared to controls has been previously found in stools (Weir
et al., 2013) but not in mucosal biopsies (Mira-Pascual et al.,
2015), and the analysis of our limited cohort is in line with this
finding. Previous studies have reported a significant decrease of
this species in IBD subjects (Png et al., 2010). Methodological
differences may explain the inconsistency with our findings, as
we exclusively focused on colonic samples. In biopsy samples,
Png and collaborators observed a reduction of this species
in IBD patients that ranged between 2.9- and 3.9-fold when
compared to controls, which is similar to the reduction observed
in our subjects. In that study (Png et al., 2010), differences
were observed depending on whether or not the tissue was
affected, with the depletion being more conspicuous in inflamed
tissue, and without reaching significant differences between non-
inflamed tissue of CD and controls, which is in line with our
results as we used non-affected tissue. In addition, we have
explored differences taking into account disease location, activity
or intestinal resection, but no association between A. muciniphila
load and these variables has been revealed. Intriguingly, CD
patients who presented with disease below 16 years of age had a
striking reduction of this species compared to those with disease
onset at a later age. A. muciniphila has been reported to colonize
the gut in early infancy, and loads in infants 1 year old are
similar to that found in adults (Collado et al., 2007). Therefore,
it seems likely that this depletion is not a general phenomenon
that occurs in IBD or age-driven, but due to particular features of
pediatric IBD that are sustained throughout the disease. In line
with this, discrepancies between dysbiosis signatures in adult and
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FIGURE 3 | Heatmap of spearman correlation cofficients between A. muciniphila, total F. prausnitzii and its phylogroups abundances, splitting up patients by
diagnostics, inflammatory bowel disease subtypes, and main clinical characteristics. Significant correlations are indicated *P < 0.05, **P < 0.01.
infant IBD patients have been previously reported (Hansen et al.,
2012) and it remains to be explored through prospective studies
if early disease onset results in long term microbial signatures.
Another future application of this finding could be to explore the
usefulness of A. muciniphila depletion as a biomarker to assist in
pediatric IBD diagnosis.
Regarding mucosa-associated F. prausnitzii loads we have
observed a marked reduction in CRC and CD patients, especially
in those with ileal involvement, affecting both phylogroups of
this species. Although less prominent, UC patients also featured
lower F. prausnitzii abundance than H subjects. Our study is
in agreement with previous reports which found F. prausnitzii
to be reduced in CRC and IBD adults (Swidsinski et al., 2005,
2008; Martinez-Medina et al., 2006; Frank et al., 2007; Sokol
et al., 2008, 2009; Willing et al., 2009; McLaughlin et al., 2010;
Vermeiren et al., 2012; Kabeerdoss et al., 2013; Machiels et al.,
2013; Miquel et al., 2013; Lopez-Siles et al., 2014, 2016). Besides,
lower abundance of both F. prausnitzii phylogroups has been
previously reported concerning CD patients (Jia et al., 2010;
Lopez-Siles et al., 2016), which is in line with our findings.
Moreover, because we have observed differences between IBD
subtypes, our results support the hypothesis that patients with
ileal disease location constitute a differentiated pathological
entity (Willing et al., 2009). We have corroborated that the
reduction of F. prausnitzii numbers compared to H subjects
takes place in both active and inactive IBD patients (Willing
et al., 2009), with active CD patients featuring the lowest
levels of phylogroup I. Also in agreement with previous studies
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(Sokol et al., 2008) lower numbers of F. prausnitzii were
detected in resected CD patients, but in our study, statistically
significant differences were only achieved for phylogroup II,
probably because the depletion was more striking. It remains
unknown why there are shifts in particular subgroups of this
species. To date, several articles convey the point that the
genus Faecalibacterium hosts a complex diversity (Lopez-Siles
et al., 2015; Benevides et al., 2017; Martín et al., 2017). This
diversity has been shown mainly through phylogenetic methods,
but phenotypical diversity also exists. Supporting this point,
studies characterizing several strains of this species isolated
from different origins have failed to find phenotypic traits that
consistently distinguish members from one or other subtype
(Lopez-Siles et al., 2012; Foditsch et al., 2014; Martín et al., 2017).
However, the effect of host factors differentially influencing
F. prausnitzii subpopulations has been poorly explored which
may explain our results. Another hypothesis could be that
subtypes of F. prausnitzii interact in a differentmanner with other
members of themicrobiome, which has also been scarcely studied
to date.
We have explored co-occurrence and correlation between
A. muciniphila and F. prausnitzii in H and IBD patients. We
considered that both species may have a syntrophic relationship,
thus we hypothesize that the depletion or enrichment of one
would imply the same effect on the other. In particular,
A. muciniphila mucolytic activity could release oligosaccharides,
co-factors, vitamins, and short chain fatty acids, including
acetate that juxtaposed species could use for growth. Indeed,
F. prausnitzii has been proven to be able to use some
oligosaccharides derived frommucus and its growth is stimulated
by acetate and requires presence of vitamins in the medium
(Duncan et al., 2002; Lopez-Siles et al., 2012). These compounds,
can be provided by A. muciniphila, although not exclusively,
and therefore establish cross-feeding interactions. A recent study
based on co-culture experiments demonstrated this trophic
interaction (Belzer et al., 2017). However, in most of the cases
studied here, we did not find a correlation between F. prausnitzii
and A. muciniphila abundances, and the two species co-occurred
only in 41.5% of subjects engaged in the study. This may
be because F. prausnitzii does not depend exclusively on by-
products synthesized by A. muciniphila. In agreement with that,
other studies have reported that F. prausnitzii can benefit from
the presence of a variety of acetate-producing species (Wrzosek
et al., 2013; Rios-Covian et al., 2015). It would be interesting
to determine whether this species (or other mucus-inhabiting
species) increase in patients in which A. muciniphila diminishes,
and thus may be partially replacing its role concerning acetate
production.
Nonetheless, we observed that positive correlation between
the two species happens in CD patients, and particularly for those
with B1 behavior or under immunosuppressant therapy. The fact
that there is a positive correlation of the two species indicates
that their abundance varies in a similar way in this particular
condition. The most likely scenario is that in CD the two bacteria
are similarly affected by host and gut environmental factors. To
support this hypothesis, both species share the characteristic that
their growth is severely compromised at pH< 5.5 (Derrien et al.,
2004; Lopez-Siles et al., 2012) and in turn, acidic stools have been
reported for IBD patients (Nugent et al., 2001; Barkas et al., 2013).
Notably, in those cases of correlation between both species, only
members of phylogroup I were involved. It would be interesting
to perform co-culture studies with different F. prausnitzii strains,
and monitor their growth under different conditions in order to
determine more accurately their relationship.
In our cohort, A. muciniphila was not detected in 57.1% of
all subjects but this seems to be related to the fact that this
species has a lower relative abundance in the gut, rather than to
a higher sensitivity to gut disease. In contrast, A. muciniphila was
more frequently found in UC patients. This could be partially
explained by the fact that a higher proportion of loose mucus
has been found in UC patients (Antoni et al., 2014), which
is the likely niche for A. muciniphila. Another hypothesis that
can not be ruled out is that some factor of UC patients favors
the presence of A. muciniphila. In our limited cohort, we have
also observed higher prevalence of this species in CRC group
compared to controls, which is in line with previous findings
(Mira-Pascual et al., 2015). However, our data points out that
this higher presence does not imply an increase in the abundance
at the mucosal level. In contrast, almost 90% of subjects were
F. prausnitzii carriers and thus the fact that it is a second-liner
in the mucosa and the fact that this species can rely on other
members of the gut microbiota for cross-feeding may explain its
higher ubiquity and abundance compared to A. muciniphila.
Finally, our study revealed that CD patients are characterized
by a low F. prausnitzii: A. muciniphila, ratio affecting both
phylogroups. This indicates that compared to H and UC, these
patients have an altered proportion of beneficial microorganisms
in the mucosa. Although our study does not allow us to decipher
if this imbalance is a cause or a consequence of the disease, it can
be an aggravator because the two species have been linked to be
key for mucus integrity (Derrien et al., 2004;Wrzosek et al., 2013)
and gut homeostasis. A significant depletion of both species has
also been reported in children with atopic disease (Candela et al.,
2012), and therapeutic strategies to restore these species needs
to be explored, particularly for disorders that have in common
to feature chronic inflammation. In addition, two recent studies
have linked the two species with response to immunotherapy
treatment (Gopalakrishnan et al., 2017; Routy et al., 2017), thus
pointing out another situation in which it is relevant to have these
bacteria. Further studies to assess implications in IBD treatment
response would be interesting, as immunomodulators are among
the usual therapies prescribed to IBD patients. Finally, further
confirmation of our results in a larger cohort would be required
given that we have engaged a limited number of subjects, and thus
it would provide robustness to those findings not sustained after
FRD assessment.
CONCLUSIONS
IBD patients are characterized by a reduction of F. prausnitzii
and a slight underrepresentation of A. muciniphila in the colonic
mucosa, regardless of disease activity status. While differences
in F. prausnitzii load have been observed for I-CD patients,
early onset CD is characterized by a lack of A. muciniphila, but
further prospective studies are required to assess if this feature
is sustained long term. Positive correlation between the two
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species was found in CD patients, and further studies are required
to elucidate which common factors alter both populations in
particular gut disorders.
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